Ondansetron HCL Tablets
Pre-Solicitation Posted
Not the latest version. See the latest solicitation from .
- Solicitation number
- SPE2D2-25-R-0017
- Agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Responses due
- Not on record
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Logistics Agency is planning to issue a solicitation for a national requirements contract for Ondansetron HCL Tablets, an anti-nausea medication used in various medical settings. The procurement includes multiple formulations: Ondansetron Hydrochloride 4mg and 8mg tablets in various bottle counts (30, 100, and 500), as well as Ondansetron Orally Disintegrating tablets in 4mg and 8mg strengths in 10 and 30 count bottles. This will be an unrestricted and fully competitive acquisition open to all qualified sources, with proposals evaluated under standard commercial item procedures using FAR Part 12. The contract will serve multiple government agencies including the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons through DLA and VA prime vendor programs. The projected solicitation date is June 2025, with interested parties advised to contact Kyle Lewicki at (445) 737-0977 for questions and to set up automated notifications through the procurement websites.
This opportunity has no set-aside designation, making it available to businesses of all sizes to compete. The contract structure will be a firm-fixed price requirements contract with a one-year base period and four one-year option periods, potentially spanning five years total. No current contractors or incumbents are identified in the pre-solicitation notice. Annual usage estimates will be provided in the Schedule of Supplies section when the formal solicitation is released, though specific quantities and award values are not disclosed at this pre-solicitation stage. The solicitation will be posted on both the DLA Bid Board System (DIBBS) and Sam.Gov when released, with DLA reserving the right to issue the solicitation before or after the projected June 2025 timeframe.
Notice text
2 versions
Update #2 · Latest ·
The Defense Logistics Agency is planning to issue a solicitation for a national requirements contract for Ondansetron Hydrochloride (HCL) Tablets. Procurement details follow.
Ondansetron Hydrochloride (HCL) 4 MG Tablet in 30, 100, and 500 count bottles.
Ondansetron Hydrochloride (HCL) 8 MG Tablet in 30 and 500 count bottles.
This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency.
A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Sam.Gov at https://sam.gov. Interested parties should contact Kyle Lewicki at (445) 737-0977, (kyle.lewicki@dla.mil) for any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current projected solicitation date is July of 2025. DLA reserves the right to issue the solicitation before or after the projected solicitation date.
*Originally, this requirement included Ondansetron 4MG Orally Dissolving Tablets (ODT) in 30 count bottles and 8MG ODTs in 10 and 30 count bottles. The ODT tablets will be solicited in a separate acquisition.
Update #1 ·
The Defense Logistics Agency is planning to issue a solicitation for a national requirements contract for Ondansetron Tablets. Procurement details follow.
Ondansetron Hydrochloride (HCL) 4 MG Tablet in 30, 100, and 500 count bottles.
Ondansetron Hydrochloride (HCL) 8 MG Tablet in 30 and 500 count bottles.
Ondansetron Orally Disintegrating (ODT) 4 MG Tablet in 30 count bottles.
Ondansetron Orally Disintegrating (ODT) 8 MG Tablet in 10 and 30 count bottles.
This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency.
A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Sam.Gov at https://sam.gov. Interested parties should contact Kyle Lewicki at (445) 737-0977, (kyle.lewicki@dla.mil) for any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current projected solicitation date is June of 2025. DLA reserves the right to issue the solicitation before or after the projected solicitation date.
Notice history
| Notice | Type | Posted |
|---|---|---|
| Ondansetron HCL Tablets | Solicitation | |
| This notice | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Methylphenidate ER | Medical Supply Chain | No set-aside | |
| 6505--Imatinib Tablets | National Acquisition Center | No set-aside | |
| 6505--Sodium Bicarbonate Injection Vial Restricted to Made in America | National Acquisition Center | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity